Aprea Therapeutics, Inc. Stock Price, News & Analysis

Aprea Therapeutics (Nasdaq: APRE) reported financial results for 2022, highlighting its focus on developing cancer therapeutics targeting DNA damage response pathways. The company initiated its Phase 1/2a clinical trial for ATR inhibitor ATRN-119 and secured approximately $5.5 million from a public offering to extend its cash runway to Q3 2024. Cash and equivalents stood at $28.8 million as of December 31, 2022. Aprea experienced a reduced operating loss of $2.7 million in Q4 2022, down from $7.8 million in Q4 2021. The year-end net loss was $112.7 million, a significant increase from $37.1 million in 2021, primarily due to acquired in-process research and development costs.

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the selection of its abstract on preclinical programs ATRN-119 and ATRN-W1051 for presentation at the AACR 2023 Annual Meeting in Orlando, Florida, scheduled for April 14-19, 2023. The poster, titled 'ATRN-119 and ATRN-W1051: Novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment,' will be presented on April 19 at 9:00 am ET, focusing on DNA damage response pathways in cancer treatment. Aprea is committed to developing synthetic lethality cancer therapeutics, with ATRN-119 currently in clinical stages for solid tumors and plans for WEE1 inhibitor IND submission.

Aprea Therapeutics, a biopharmaceutical company focused on cancer therapeutics, announced that CEO Oren Gilad will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023, at 10:00 a.m. ET. The presentation will provide a corporate overview and will be accessible via a live webcast on the company's website, followed by a replay available for 90 days. Aprea is developing innovative drugs targeting DNA damage response pathways, with its lead program being ATRN-119, aimed at treating solid tumors. The company emphasizes its commitment to disclosing material information via its investor relations platform.

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that it has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Global Select Market. This achievement follows a recent financing round supported by quality institutions, which strengthened its balance sheet. Aprea is focused on developing cancer therapeutics targeting DNA damage response pathways, with its lead program being ATRN-119, currently in clinical trials. The company is also advancing a WEE1 inhibitor toward IND submission.

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the closing of a public offering of 1,050,000 shares at $5.25 per share, generating gross proceeds of approximately $5.5 million. The offering includes a 30-day option for underwriters to purchase an additional 157,500 shares. Net proceeds will fund the development of clinical asset ATRN-119 and pre-clinical asset ATRN-W1051, along with general corporate purposes. The offering was conducted under an effective shelf registration statement filed with the SEC. Maxim Group LLC served as the sole book-running manager.

Aprea Therapeutics (Nasdaq: APRE) has priced its underwritten public offering of 1,050,000 shares of common stock at $5.25 per share, expecting gross proceeds of approximately $5.5 million before expenses. The underwriter has a 30-day option to purchase an additional 157,500 shares. The net proceeds will be used for the development of clinical asset ATRN-119 and pre-clinical asset ATRN-W1051, alongside general corporate purposes. Maxim Group LLC is the sole book-running manager. The offering is made under an effective shelf registration statement with the SEC. Detailed offering documents are available on the SEC’s website.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focusing on novel cancer therapeutics, has announced an underwritten public offering of its common stock. All shares in this offering will be sold by Aprea, and the underwriter is granted a 30-day option to purchase an additional 15% of the shares. The offering is subject to market conditions. This move is part of Aprea's strategy to further advance its synthetic lethality-based therapies targeting DNA damage response pathways, including its clinical-stage ATR inhibitor program. Maxim Group LLC is the sole book-running manager for this offering.

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced receiving an award notification from the National Cancer Institute (NCI) for developing a first-in-class combination of DNA damage response inhibitors to treat high-grade serous ovarian cancer (HGSOC). The funding totals up to $1,996,571 over two years, contingent on project progress. HGSOC claims approximately 125,000 lives globally each year, with many cases harboring genetic mutations. Aprea will initiate a first-in-human clinical trial for its ATR inhibitor, ATRN-119, and its WEE1 inhibitor, ATRN-W1051. The grant aims to evaluate the efficacy of both agents against HGSOC.